Výsledky vyhledávání - "Luis M, Isola"

Supplemental Table 1 from Impact of Chronic Graft-versus-Host Disease on Late Relapse and Survival on 7,489 Patients after Myeloablative Allogeneic Hematopoietic Cell Transplantation for Leukemia

Supplemental Table 1. Multivariate analysis of late relapse, transplant-related mortality, overall survival after HCT for each disease (AML, ALL, CML, MDS)

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9a8b6bb0ec143b555d4baa55cd9d07bc
https://doi.org/10.1158/1078-0432.22459019.v1

Zobrazit plný text záznamu

Data from Impact of Chronic Graft-versus-Host Disease on Late Relapse and Survival on 7,489 Patients after Myeloablative Allogeneic Hematopoietic Cell Transplantation for Leukemia

Purpose: Malignancy relapse remains a major obstacle for successful allogeneic hematopoietic cell transplantation (HCT). Chronic graft-versus-host disease (cGVHD) is associated with fewer relapses. However, when studying effects of cGVHD on relapse,

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1562e3003d7ce693a7bac43e825778d3
https://doi.org/10.1158/1078-0432.c.6524114.v1

Zobrazit plný text záznamu

Supplemental Table 4 from Impact of Chronic Graft-versus-Host Disease on Late Relapse and Survival on 7,489 Patients after Myeloablative Allogeneic Hematopoietic Cell Transplantation for Leukemia

Supplemental Table 4. Multivariate analysis showing impact of cGVHD characteristics on treatment related mortality, disease free survival, overall survival in patients with AML, ALL, MDS who developed cGVHD

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::96a29a4f89ff9eb180a33441e9c479c0
https://doi.org/10.1158/1078-0432.22459010.v1

Zobrazit plný text záznamu

Supplemental Table 2 from Impact of Chronic Graft-versus-Host Disease on Late Relapse and Survival on 7,489 Patients after Myeloablative Allogeneic Hematopoietic Cell Transplantation for Leukemia

Supplemental Table 2. Multivariate analysis showing impact of cGVHD characteristics in CML patients on relapse

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bd075a41ef6607b9609e016590c0139a
https://doi.org/10.1158/1078-0432.22459016

Zobrazit plný text záznamu

Supplemental Table 3 from Impact of Chronic Graft-versus-Host Disease on Late Relapse and Survival on 7,489 Patients after Myeloablative Allogeneic Hematopoietic Cell Transplantation for Leukemia

Supplemental Table 3. Multivariate analysis showing impact of cGVHD characteristics on treatment related mortality, disease free survival and overall survival in patients with CML who developed cGVHD

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::17f3f162450909dadf1eee374d2d4530
https://doi.org/10.1158/1078-0432.22459013.v1

Zobrazit plný text záznamu

Supplemental Figure 1 from Impact of Chronic Graft-versus-Host Disease on Late Relapse and Survival on 7,489 Patients after Myeloablative Allogeneic Hematopoietic Cell Transplantation for Leukemia

Supplemental Figure 1. Cumulative incidence of cGVHD, relapse and death in patients with AML, ALL, CML, MDS

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4ff0a47fd6e908c56333b879a03134c9
https://doi.org/10.1158/1078-0432.22459022.v1

Zobrazit plný text záznamu

Severe post-treatment leukopenia associated with the development of encephalopathy following ifosfamide infusion

Autor: Luis M. Isola, William Oh, Sara Kim

Publikováno v: Anti-Cancer Drugs. 27:235-238

Ifosfamide has been shown to be associated with encephalopathy in 10-40% of patients. Although it is a well-documented toxicity associated with ifosfamide therapy, an anecdotal upsurge in its occurrence at our institution prompted us to review ifosfa

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f8abe1685db027074dd083f23293c489
https://doi.org/10.1097/cad.0000000000000321

Zobrazit plný text záznamu

Prospective study of mobilization kinetics up to 18 hours after late-afternoon dosing of plerixafor

Autor: Patricia A, Shi, Lorraine K, Miller, Luis M, Isola

Publikováno v: Transfusion. 54(5)

The current FDA-approved time interval between plerixafor dosing and apheresis initiation is approximately 11 hours, but this time interval is impractical for most care providers. Few studies have examined mobilization kinetics beyond 11 hours in mul

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::a34d4cb5df485738a245a3f2ea40d883
https://pubmed.ncbi.nlm.nih.gov/24128272

Zobrazit plný text záznamu

Phase I Study of Rituximab-Cyclophosphamide (R-CY) Stem Cell Mobilization and Rituximab-BEAM HDC with ASCT in Patients with Relapsed, Refractory or High Risk Intermediate Grade Non-Hodgkin’s Lymphoma

Autor: Luis M. Isola, John P. Mandeli, Janice L. Gabrilove, Steven M. Fruchtman, Celia L. Grosskreutz, Eileen Scigliano

Publikováno v: Blood. 104:5225-5225

The addition of rituximab to mobilization regimens does not adversely affect collection of adequate numbers of CD34+ PBSC and may decrease tumor cell contamination. Prior administration of rituximab may sensitize lymphoma cells to chemotherapy, but i

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::4ffb3622b1e931c849e86fc4e07a096e
https://doi.org/10.1182/blood.v104.11.5225.5225

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání